Emergent BioSolutions Inc.
EBS
$5.08
$0.265.39%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 770.20M | 676.80M | 742.90M | 788.90M | 851.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 770.20M | 676.80M | 742.90M | 788.90M | 851.60M |
| Cost of Revenue | 372.70M | 342.90M | 363.10M | 392.10M | 422.70M |
| Gross Profit | 397.50M | 333.90M | 379.80M | 396.80M | 428.90M |
| SG&A Expenses | 181.10M | 180.20M | 186.00M | 195.10M | 232.70M |
| Depreciation & Amortization | 66.30M | 65.30M | 65.10M | 65.10M | 65.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 628.50M | 600.30M | 626.10M | 663.80M | 731.80M |
| Operating Income | 141.70M | 76.50M | 116.80M | 125.10M | 119.80M |
| Income Before Tax | -146.00M | 3.50M | 82.80M | 105.90M | 190.70M |
| Income Tax Expenses | 30.80M | 12.10M | 30.20M | 30.00M | 51.20M |
| Earnings from Continuing Operations | -176.80 | -8.60 | 52.60 | 75.90 | 139.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -176.80M | -8.60M | 52.60M | 75.90M | 139.50M |
| EBIT | 141.70M | 76.50M | 116.80M | 125.10M | 119.80M |
| EBITDA | 233.60M | 167.90M | 210.10M | 221.20M | 218.60M |
| EPS Basic | -3.44 | -0.17 | 0.95 | 1.41 | 2.61 |
| Normalized Basic EPS | 1.11 | 0.23 | 0.63 | 0.79 | 1.11 |
| EPS Diluted | -3.55 | -0.28 | 0.84 | 1.30 | 2.45 |
| Normalized Diluted EPS | 1.05 | 0.17 | 0.55 | 0.71 | 1.03 |
| Average Basic Shares Outstanding | 209.10M | 211.70M | 214.20M | 216.00M | 215.90M |
| Average Diluted Shares Outstanding | 217.00M | 219.60M | 220.40M | 222.20M | 221.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |